9969 주식 개요 이노케어 파마는 중국에서 암 및 자가 면역 질환 치료를 위한 의약품을 발굴, 개발 및 상용화하는 바이오 제약 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
InnoCare Pharma Limited 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 InnoCare Pharma 과거 주가 현재 주가 HK$5.93 52주 최고치 HK$7.92 52주 최저치 HK$4.03 베타 1.02 1개월 변경 -9.05% 3개월 변경 사항 2.95% 1년 변경 사항 -7.49% 3년 변화 -60.57% 5년 변화 n/a IPO 이후 변화 -39.55%
최근 뉴스 및 업데이트 더 많은 업데이트 보기
Pinning Down InnoCare Pharma Limited's (HKG:9969) P/S Is Difficult Right Now Dec 18
Consensus estimates of losses per share improve by 19% Nov 18
Third quarter 2024 earnings released: CN¥0.007 loss per share (vs CN¥0.062 loss in 3Q 2023) Nov 12
Is InnoCare Pharma (HKG:9969) A Risky Investment? Oct 21
InnoCare Pharma Limited Announces Phase II Clinical Study of Icp-488 for the Treatment of Moderate-To-Severe Plaque Psoriasis Oct 10
InnoCare Pharma Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients Oct 09
InnoCare Pharma Limited to Report Q3, 2024 Results on Nov 12, 2024 Sep 30
InnoCare Pharma Limited Announces Board and Committee Changes Sep 25
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China Sep 19
Subdued Growth No Barrier To InnoCare Pharma Limited (HKG:9969) With Shares Advancing 29% Sep 13
InnoCare Pharma Limited Announces End of Phase 2 Meeting with the U.S. Food and Drug Administration Regarding the Clinical Development of Orelabrutinib for the Treatment of Multiple Sclerosis Sep 10
Consensus estimates of losses per share improve by 12% Aug 27
Analyst Estimates: Here's What Brokers Think Of InnoCare Pharma Limited (HKG:9969) After Its Half-Yearly Report Aug 22
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 21
InnoCare Pharma Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S Jul 24
InnoCare Pharma Limited to Report First Half, 2024 Results on Aug 21, 2024 Jun 28
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt? Jun 21
InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China Jun 20
InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis May 16
First quarter 2024 earnings released: CN¥0.08 loss per share (vs CN¥0.007 loss in 1Q 2023) May 14
Consensus revenue estimates decrease by 16% Apr 04
Some Analysts Just Cut Their InnoCare Pharma Limited (HKG:9969) Estimates Apr 02 InnoCare Pharma Limited to Report Q1, 2024 Results on May 14, 2024
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 29
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib Mar 29
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China Mar 13
Is InnoCare Pharma (HKG:9969) Weighed On By Its Debt Load? Feb 14
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023 Jan 29
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China Jan 24
InnoCare Pharma Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA Jan 16
New minor risk - Profitability Dec 28 InnoCare Pharma Appoints Xin Fu as Chief Financial Officer
InnoCare Pharma Announces Latest Data of Oncology Pipelines Presented at the 65th Annual Meeting of ASH Dec 11
Third quarter 2023 earnings released: CN¥0.062 loss per share (vs CN¥0.28 loss in 3Q 2022) Nov 14
New minor risk - Profitability Oct 31
InnoCare Pharma Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China Oct 27
Innocare Pharma Limited Announces the Appointment of Dandan Dong as Independent Non-Executive Director Oct 12
Health Check: How Prudently Does InnoCare Pharma (HKG:9969) Use Debt? Oct 06
InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023. Sep 22
InnoCare Pharma Limited (SEHK:9969) commences an Equity Buyback Plan for 149,967,323 shares, representing 8.5% of its issued share capital, under the authorization approved on June 2, 2023. Sep 21
InnoCare Pharma Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib Sep 14
InnoCare Announces Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology Sep 13
Second quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.24 loss in 2Q 2022) Sep 02
Innocare Pharma Limited Announces Board Changes Jul 15
InnoCare Pharma Limited to Report First Half, 2023 Results on Aug 30, 2023 Jun 28
Consensus EPS estimates upgraded to CN¥0.38 loss May 16
Is InnoCare Pharma (HKG:9969) Using Too Much Debt? May 11
First quarter 2023 earnings released: CN¥0.01 loss per share (vs CN¥0.08 loss in 1Q 2022) May 10
No longer forecast to breakeven Apr 27
Is There An Opportunity With InnoCare Pharma Limited's (HKG:9969) 36% Undervaluation? Apr 11
No longer forecast to breakeven Mar 30
Forecast breakeven date pushed back to 2025 Mar 29
Forecast breakeven date pushed back to 2025 Feb 16
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2022 Jan 30
InnoCare Pharma Limited Announces the Latest Clinical Result of FGFR Inhibitor Gunagratinib (ICP-192) for the Treatment of Cholangiocarcinoma Was Presented At 2023 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium Jan 28
Is InnoCare Pharma (HKG:9969) A Risky Investment? Jan 25
InnoCare Pharma Limited Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong Dec 28
Now 27% undervalued Dec 28
No longer forecast to breakeven Dec 27
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China Dec 21
InnoCare Pharma Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore Nov 22
Consensus revenue estimates increase by 12% Nov 20
Third quarter 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.17 profit in 3Q 2021) Nov 16
Less than half of directors are independent Nov 16
InnoCare Pharma Limited to Report Nine Months, 2022 Results on Nov 11, 2022 Nov 02
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China Oct 31
Forecast to breakeven in 2024 Oct 22 InnoCare Pharma Limited has completed a Follow-on Equity Offering in the amount of CNY 2.672498 billion. Sep 15
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China Sep 13
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China Sep 10
InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA Sep 07
InnoCare Pharma Limited Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA Sep 06
Despite Lacking Profits InnoCare Pharma (HKG:9969) Seems To Be On Top Of Its Debt Sep 05
No longer forecast to breakeven Sep 03
No longer forecast to breakeven Sep 01
InnoCare Pharma Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong Aug 31
Consensus revenue estimates fall by 10% Aug 28
InnoCare Pharma and Keymed Biosciences Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369 Aug 24
First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.16 loss in 1H 2021) Aug 23
InnoCare Pharma Limited Provides Earnings Guidance for the Nine Months Ended 30 September 2022 Aug 23
InnoCare Pharma Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China Aug 12
Innocare Pharma Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 Aug 06
InnoCare Pharma Limited Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China Aug 02
Innocare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Boao Hope City’s Early Access Program Jul 22
InnoCare Pharma Limited Announces Approval of Clinical Trial of Novel Targeted Protein Degrader Icp-490 in China Jul 09
InnoCare Pharma Limited Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China Jun 22
Innocare Announces Approval to Conduct A Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China May 27
InnoCare Pharma (HKG:9969) Is Using Debt Safely Apr 30
Less than half of directors are independent Apr 27
InnoCare Presents Pre-Clinical Data of ICP-723 at AACR Annual Meeting 2022 Apr 11
Innocare Pharma Limited Announces Executive Changes Apr 01 주주 수익률 9969 HK Biotechs HK 마켓 7D -3.9% -3.9% -0.5% 1Y -7.5% -5.7% 19.9%
전체 주주 수익률 보기
수익률 대 산업: 9969 지난 1년 동안 -5.7 %를 반환한 Hong Kong Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 9969 지난 1년 동안 19.9 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 9969's price volatile compared to industry and market? 9969 volatility 9969 Average Weekly Movement 9.1% Biotechs Industry Average Movement 11.1% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
안정적인 주가: 9969 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 9969 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 이노케어 파마는 중국에서 암 및 자가면역 질환 치료를 위한 약물을 발굴, 개발 및 상용화하는 바이오 제약 회사입니다. 이 회사는 재발성 및/또는 불응성(r/r) 만성 림프구성 백혈병, r/r 맨틀세포 림프종, r/r 월든스트롬 거대글로불린혈증, r/r 변연부 림프종 환자 치료를 위한 BTK 억제제인 오랄라브루티닙을 개발합니다, 미만성 거대 B세포 림프종(DLBCL)- MCD, 미만성 중추신경계 림프종, 복합형/MIL-62, 전신 홍반성 루푸스, 면역성 혈소판 감소증 자반증, 다발성 경화증, 시신경척수염 스펙트럼 장애. 또한 담관암, 두경부암 등 고형암 환자 치료를 위해 임상 1상/2상을 진행 중인 범상피세포성장인자수용체증식인자수용체(pan-FGFR) 억제제 ICP-192와 신경영양성 티로신 수용체 키나제 융합 양성 암 치료를 위해 임상 1상 중인 범-TRK 억제제 ICP-723을 개발 중입니다; 자가면역질환 치료를 위한 임상 1상 시험 중인 신규 티로신 키나제 2 억제제 ICP-332, 림프종 치료를 위한 이중특이성 항체 ICP-B02 등을 개발하고 있습니다.
자세히 보기 InnoCare Pharma Limited 기본 사항 요약 InnoCare Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요? 9969 기본 통계 시가총액 HK$12.45b 수익(TTM ) -HK$400.19m 수익(TTM ) HK$958.01m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 9969 손익 계산서(TTM ) 수익 CN¥898.92m 수익 비용 CN¥125.58m 총 이익 CN¥773.34m 기타 비용 CN¥1.15b 수익 -CN¥375.51m
주당 순이익(EPS) -0.21 총 마진 86.03% 순이익 마진 -41.77% 부채/자본 비율 20.9%
9969 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/21 19:06 장 마감 주가 2024/12/20 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 InnoCare Pharma Limited 17 애널리스트 중 9 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Peng Zou China International Capital Corporation Limited Tan Huan Gan Citic Securities Co., Ltd. Shitong Han Citic Securities Co., Ltd.
14 더 많은 분석가 보기 
